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Background: We investigated whether right ventricular dysfunction (RVD) as assessed by echocardiogram can be
used as a prognostic factor in hemodynamically stable patients with acute pulmonary embolism (PE). Short-term
mortality has been investigated only in small studies and the results have been controversial.
Methods: A PubMed search was conducted using two keywords, “pulmonary embolism” and “echocardiogram”, for
articles published between January 1st 1998 and December 31st 2011. Out of 991 articles, after careful review, we
found 12 articles that investigated the implications of RVD as assessed by echocardiogram in predicting short-term
mortality for hemodynamically stable patients with acute PE. We conducted a meta-analysis of these data to identify
whether the presence of RVD increased short-term mortality.
Results: Among 3283 hemodynamically stable patients with acute PE, 1223 patients (37.3%) had RVD, as assessed
by echocardiogram, while 2060 patients (62.7%) had normal right ventricular function. Short-term mortality was
reported in 167 (13.7%) out of 1223 patients with RVD and in 134 (6.5%) out of 2060 patients without RVD.
Hemodynamically stable patients with acute PE who had RVD as assessed by echocardiogram had a 2.29-fold
increase in short-term mortality (odds ratio 2.29, 95% confidence interval 1.61-3.26) compared with patients
without RVD.
Conclusions: In hemodynamically stable patients with acute PE, RVD as assessed by echocardiogram increases
short-term mortality by 2.29 times. Consideration should be given to obtaining echocardiogram to identify high-risk
patients even if they are hemodynamically stable.
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Acute pulmonary embolism (PE), commonly originating
from deep venous thrombosis (DVT), is a potentially
life-threatening condition. PE incidence is approximately
69 per 100,000 according to a 25-year population-based
study [1]. PE can be broadly classified as either massive or
submassive. Patients with massive PE usually present with
hemodynamic instability and are treated with either* Correspondence: choj2@ccf.org
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unless otherwise stated.thrombolytic therapy or pulmonary embolectomy, while
patients with submassive PE are generally hemodynamically
stable and can be treated with anticoagulation alone. Recent
evidence suggests that in selected low-risk patients with
acute PE, outpatient care can be as safe and effective as
inpatient care [2].
Untreated PE patients reportedly have a 30% mortality
rate, whereas treated PE patients have an 8% mortality
rate [3]. PE can cause right ventricular dilatation and
dysfunction because of increased right ventricular afterload,
leading to right ventricular failure and subsequently death.
Echocardiogram is essential in ruling out intracardiac. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ventricular dysfunction (RVD). Few studies have inves-
tigated the prognostic implications of RVD as assessed
by echocardiogram in hemodynamically stable patients
with acute PE and the results have been controversial.
There have been two previous meta-analyses regarding the
assessment of RVD by echocardiogram in hemodynamically
stable patients with acute PE that revealed increased
short-term mortality [4,5]. However, the clinical impact of
RVD as assessed by echocardiogram is still controversial
and current venous thromboembolism guidelines do not
recommend the routine echocardiogram to assess right
ventricular function in hemodynamically stable patients
with acute PE [6]. Hence, we conducted a new meta-
analysis to examine the implication of RVD as assessed




Few studies have studied whether RVD as assessed by
echocardiogram increases short-term mortality (in-
hospital or 30-day mortality) in hemodynamically stable
patients with acute PE, which is controversial. The
objective of this meta-analysis is to assess the prog-
nostic value of RVD determination on echocardiogram
in hemodynamically stable patients with acute PE.
We followed the PRISMA statements for reporting
meta-analyses.
Study outcome
The study outcome of our meta-analysis was short-term
mortality, which included in-hospital and 30-day mortality.
Studies that investigated adverse clinical events such as
intubation, cardiopulmonary resuscitation or the use of
vasopressors, were excluded. Studies with 14-day, 3-month
or 6-month mortality were also excluded to decrease
meta-analysis heterogeneity.
Search strategy
We searched PubMed using two keywords, “pulmonary
embolism” and “echocardiogram”. Search criteria included
the time frame between January 1st 1998 and December
31th 2011, humans, English, and adults older than 19
years. A total of 991 articles were included in our initial
search. The articles were independently reviewed by two
authors (J.H.C. and G.K.S.). The initial screening was
performed by first reviewing the titles and the abstracts
were reviewed if they contained text describing the
prognostic value of RVD assessment. After reviewing
the titles and abstracts, 106 articles were selected for
full review. In total, eighteen out of 106 studies investi-
gated the implications of RVD as assessed by echocar-
diogram in hemodynamically stable patients with acutePE. The rest of the eighty-eight studies were excluded
for the following reasons: they were not investigational
studies, they had different study objectives, they used
different patient populations such as hemodynamically
unstable PE or chronic PE, or they used different RVD
diagnostic modalities such as CT, cardiac biomarkers
or brain natriuretic peptide (BNP). In total, six studies
had different clinical outcomes such as 14-day, 40-day,
3-month mortality or adverse clinical outcomes, which
were excluded. Finally, twelve studies were selected for
our meta-analysis (Figure 1). The disagreements be-
tween these two authors were reviewed and the two
disagreeing studies were excluded because of different
clinical outcomes. After meticulous review, the data
were extracted independently by the two aforementioned
authors using standard data extraction forms and were
confirmed together.
Eligibility criteria
We used studies that included only hemodynamically stable
patients with acute PE. We excluded hemodynamically
unstable patients with acute PE. Hemodynamic instability
was defined as systolic blood pressure less than 90 mmHg
or a systolic blood pressure drop greater than 40 mmHg
from the baseline. We also excluded patients with chronic
PE. We selected studies that investigated the implications
of RVD assessment by echocardiogram to predict short-
term mortality, which includes in-hospital or 30-day
mortality. RVD can be assessed by echocardiogram, CT,
cardiac biomarkers or BNP. However, we only included
studies that investigated RVD using echocardiogram.
We excluded studies that focused on mortality other
than in-hospital or 30-day. We excluded studies that in-
vestigated adverse clinical outcomes such as intubation,
cardiopulmonary resuscitation or vasopressor use.
Statistical analysis
We performed meta-analysis using RevMan 5.0 with the
Mantel-Haenszel random effects model. Cochran’s
chi-square test and the I2 test were used to assess
between-study heterogeneity. Heterogeneity was con-
sidered statistically significant at P < 0.10 and I2 > 50%.
Pooled odds ratios were reported with 95% confidence
intervals.
Subgroup analyses
Subgroup analyses were performed according to the out-
come measure (in-hospital mortality vs. 30-day mortality)
and the study design (prospective vs. retrospective).
Results
Study selection
A total of 991 articles were included in our initial search.
After a thorough review of titles and abstracts, 106 journals
Figure 1 Study selection.
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full articles, 12 studies (n = 3283) were selected for data
extraction and meta-analysis.Study characteristics
A total of 3283 patients were included in our meta-
analysis. Individual characteristics of the included
studies are shown in Table 1. As a study outcome, nine
studies measured in-hospital mortality while three studies
investigated 30-day mortality. In total, seven studies were
prospective whereas five studies were retrospective. The
qualitative findings of included studies using Newcastle-
Ottawa quality assessment scale are described in Table 2.Right ventricular dysfunction as assessed by echocardiogram
The American Society of Echocardiography published
“Guidelines for the Echocardiographic Assessment of the
Right Heart in Adults” in 2010 [19]. However, because
most of our studies were performed before this guideline
was published, the definition of RVD as assessed by
echocardiogram differed from study to study. The
echocardiographic criteria of RVD in each study are
described in Table 1. The most commonly used criteria
were: right ventricular end-diastolic diameter > 30 mm,
right ventricular/left ventricular end-diastolic diameter > 1
or right ventricular hypokinesia. Other criteria includedparadoxical septal wall motion, pulmonary hypertension
and severe tricuspid regurgitation.
Right ventricular dysfunction predicting in-hospital or
30-day mortality
Among 3283 hemodynamically stable patients with
acute PE, 1223 patients (37.3%) had RVD as assessed by
echocardiogram while 2060 patients (62.7%) had normal
right ventricular function. Short-term mortality was re-
ported in 167 (13.7%) out of 1223 patients with RVD
and in 134 (6.5%) out of 2060 patients without RVD.
Hemodynamically stable patients with acute PE who
had RVD as assessed by echocardiogram had a 2.29-fold
increase in short-term mortality (Figure 2) (odds ratio
(OR) 2.29, 95% confidence interval (CI) 1.61-3.26) com-
pared with patients without RVD.
Subgroup analyses
Subgroup analyses demonstrated that patients with RVD
as assessed by echocardiogram had a 2.60-fold increase
in in-hospital mortality (Figure 3) and a 1.98-fold increase
in 30-day mortality (Figure 4) (OR 2.60, 95% CI 1.43-4.72,
and OR 1.98, 95% CI 1.43-2.73, respectively). Prospective
study subgroup analysis revealed that patients with RVD
as assessed by echocardiogram had a 1.61-fold increase in
short-term mortality (Figure 5) while retrospective studies
demonstrated a 2.92-fold increase in short-term mortality







Diagnostic nodality RVD Definition Follow-up RVD (+) RVD (-)
Death Total Death Total
1 Grifoni et al. [7]
(Circulation)




In-hospital mortality 4 65 3 97
2 Yalamanchili et al. [8]
(Am J Cardiol)
2004 Retrospective 91 CT RVEDD>30mm, or
RVHK and PSWM
In-hospital mortality 4 25 8 66
3 Kucher et al. [9]
(Arch Intern Med)
2005 Retrospective 1035 Necropsy, V/Q scan, pulmonary
angiography or high suspicion in
the setting of DVT
RVHK 30-day mortality 65 405 59 630
4 Sukhija et al. [10]
(Am J Cardiol)
2005 Retrospective 190 CT Right ventricular dilatation
(RV>LV, or RV>4.5cm)
In-hospital mortality 21 64 6 126
5 Grifoni et al. [11]
(Arch Intern Med)




In-hospital mortality 24 146 21 155
6 Pieralli et al. [12]
(Am J Cardiol)
2006 Prospective 61 CT or pulmonary angiography RVEDD>30mm, RV/LV>1,
RVHK, PSWM, or PH
In-hospital mortality 4 35 0 26
7 Jimenez et al. [13]
(Arch Bronchoneumol)
2007 Prospective 214 CT or V/Q scan RVEDD>30mm, RV>LV, or RVHK 30-day mortality 4 86 3 128
8 Logeart et al. [14]
(Intensive Care Med)
2007 Prospective 67 CT or V/Q scan Two or more of RV/LV>0.7,
RVHK, IVC>10mm during inspiration,
IVC bulging, TRV>2.7m/s
In-hospital mortality 1 36 0 31
9 Palmieri et al. [15]
(Intern Emerg Med)
2008 Prospective 89 CT RV/LV>0.9, PSWM, or depressed
RV systolic function
In-hospital mortality 8 48 4 41
10 Gallotta et al. [16]
(Int J Cardio)
2008 Prospective 90 CT PSWM, RV diameter>15mm/m2,
or low RV systolic function
In-hospital mortality 10 65 2 25
11 Stein et al. [17]
(Am J Cardio)
2011 Retrospective 392 CT or V/Q scan Quantitative in 325 patients,
or RV/LV>1 in 67 patients
In-hospital mortality 4 264 8 128
12 Jimenez et al. [18]
(Thorax)
2011 Retrospective 591 CT, V/Q scan or high suspicion
in the setting of DVT
RVEDD>30mm, RV>LV, RVHK,
or TRV>2.6m/s
30-day mortality 14 120 24 471
RVEDD (Right ventricular end-diastolic diameter in precordial view), RV/LV (Right ventricular/left ventricular end-diastolic diameter in 4-chamber view), PSWM (Paradoxical septal wall motion), PH (Pulmonary hypertension),









































1 Grifoni et al. [7]
(Circulation)
1 1 1 1 1 1 1 1 8
2 Yalamanchili et al. [8]
(Am J Cardiol)
1 1 1 1 0 1 1 1 7
3 Kucher et al. [9]
(Arch Intern Med)
0 1 1 1 1 1 1 1 7
4 Sukhija et al. [10]
(Am J Cardiol)
0 1 1 1 0 1 1 1 6
5 Grifoni et al. [11]
(Arch Intern Med)
1 1 1 1 1 1 1 1 8
6 Pieralli et al. [12]
(Am J Cardiol)
1 1 1 1 1 1 1 1 8
7 Jimenez et al. [13]
(Arch Bronchoneumol)
1 1 1 1 1 1 1 1 8
8 Logeart et al. [14]
(Intensive Care Med)
1 1 1 1 1 1 1 1 8
9 Palmieri et al. [15]
(Intern Emerg Med)
1 1 1 1 0 1 1 1 7
10 Gallotta et al. [16]
(Int J Cardio)
1 1 1 1 0 1 1 1 7
11 Stein et al. [17]
(Am J Cardio)
0 1 1 1 0 1 1 1 6
12 Jimenez et al. [18]
(Thorax)




















Figure 2 Meta-analysis of short-term mortality (In-Hospital or 30-Day Mortality).
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CI 1.58-5.42, respectively).
Risk of bias
To decrease the risk of bias, two authors independently
assessed the validity of the included studies at the out-
come level. To increase homogeneity, we only included
studies with clinical outcomes of either in-hospital or
30-day mortality. There might be a publication bias
despite meticulous database searches because small
negative studies or positive studies without statistical sig-
nificance might not get published. To minimize selection
bias we used very clear inclusion and exclusion criteria.
Discussion
RVD has long been thought to be a cause of death in
patients with acute PE. Right ventricular function canFigure 3 Meta-analysis of in-hospital mortality.be assessed using echocardiogram, CT, cardiac bio-
markers or BNP. Several studies investigated the impli-
cation of elevated cardiac biomarkers or BNP levels
and concluded that patients with elevated levels have
an increased mortality rate [4,5,20]. Because patients
with congestive heart failure, chronic kidney disease,
stroke or other pulmonary disease may also have ele-
vated baseline cardiac biomarker or BNP levels, there
are limitations to assess right ventricular function.
However, an echocardiogram is more specific to assess
right ventricular function because we can directly image
the right ventricle with the echocardiogram, which is not
influenced by other co-morbidities.
Recent studies suggest that certain patients with
low-risk profiles can be managed safely at home with-
out hospitalization [2]. High-risk profiles include old
age, congestive heart failure, chronic lung disease,
Figure 4 Meta-analysis of 30-day mortality.
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respiratory rate > 30 breaths per min or arterial oxygen
saturation < 90% according to the pulmonary embolism
severity index [21,22]. Our meta-analysis indicated that
patients with RVD as assessed by echocardiogram should
be regarded as high-risk because RVD increases short-
term mortality. However, the current guidelines of venous
thromboembolism do not recommend the routine use of
cardiac biomarkers, BNP, CT or echocardiogram to assess
right ventricular function in hemodynamically stable pa-
tients because it will not change patient management [6].
The positive predictive value of mortality on the basis of
echocardiographic evidence of RVD in hemodynamically
stable patients has generally been reported to be in the 5
to 8% range [7,13]. We suggest consideration be given to
obtaining echocardiogram with special emphasis on right
ventricular wall motion in normotensive patients with
acute PE, especially when they have dyspnea, tachypnea or
tachycardia.
The use of RVD as assessed by echocardiogram as a
prognostic factor in acute PE has been controversial.
As described in our included studies, eight out of
twelve studies demonstrated non-significant results in
predicting mortality [7,8,11-16]. Only four studies re-
vealed a statistically significantly increased mortalityFigure 5 Meta-analysis of prospective studies.rate [9,10,17,18]. There have been two previous meta-
analyses regarding RVD assessment by echocardiogram.
Sanchez et al. included five studies and Coutance et al.
included eight studies [4,5]. However, the clinical outcome
of these meta-analyses had wide variations from in-hospital
mortality to 14-, 30- or 40-day mortality [4,5]. Our
meta-analysis included 12 studies with uniform clinical
outcomes of either in-hospital or 30-day mortality.
Short-term mortality, which includes in-hospital or 30-day
mortality, was increased 2.29-fold in patients with RVD as
assessed by echocardiogram. Subgroup analyses revealed
that patients with RVD as assessed by echocardiogram
have a 2.60-fold increase in in-hospital mortality and a
1.98-fold increase in 30-day mortality. None of these
meta-analyses demonstrated significant heterogeneity.
Although treatment of RVD without hemodynamic
instability among patients with PE was not within the
scope of our meta-analysis, several studies have addressed
this issue [23-25]. The most recent study randomized
patients with intermediate-risk PE (as defined by RVD
on echocardiogram or spiral CT and myocardial injury
as defined by troponin elevation) to thrombolytic agent
(tenecteplase) vs. intravenous heparin [25]. Decreased
composite of hemodynamic instability and death (2.6%)
but higher risk of hemorrhagic stroke (2.0%) and major
Figure 6 Meta-analysis of retrospective studies.
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treated with tenecteplase, thus advising cautious use of
thrombolytic agent among hemodynamically stable patients
with RVD [25].
There are several limitations to our meta-analysis.
First, we used only one database for the study selection.
PubMed is the major search engine for medical literature;
however, we could increase the power of our meta-analysis
by including other search engines such as Cochrane or
Embase. Even using only with PubMed, we found sig-
nificant studies with adequate homogeneity. Second,
the definition of RVD as assessed by echocardiogram
differed among the studies (Table 1). In particular, in
the study by Sukhija et al. it is possible that too stringent
criteria for RVD (RV > LV, or RV > 4.5 cm) were used
which may have contributed to a very high OR for
short-term mortality [10]. In light of such high short-
term mortality, it is also possible that even though the
patients in this study were classified as hemodynamically
stable, some of them may really have had some clinical
clue or deterioration which was missed. Although the
American Society of Echocardiography published a guide-
line of assessing the right heart in an adult population in
2010, most of the studies were performed before the
publication of this guideline [19]. In the future, the
homogeneity can be increased and subgroup analysis of
different echocardiographic RVD criteria can be performed
if we have sufficient studies that followed this guideline.
Third, it is hard to assess whether RVD is an acute finding
secondary to PE or a chronic condition because of other
co-morbidities because most of these patients do not have
a baseline echocardiogram to check right ventricular func-
tion. Differentiation of acute versus chronic RVD would
also be difficult solely on echocardiographic findings. Be-
cause it is not practical to obtain a baseline echocardio-
gram before PE development, this assessment will remain a
future research area. Lastly, some studies in the meta-
analysis lacked stringent exclusion criteria and it is possible
that hemodynamic instability was under-reported.Conclusions
In hemodynamically stable patients with acute PE, RVD
as assessed by echocardiogram increases short-term
mortality by 2.29 times. Consideration should be given to
obtaining echocardiogram to identify high-risk patients
even if they are hemodynamically stable.
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